Amgen Inc. closed 16.06% short of its 52-week high of $346.85, which the company reached on July 25th.

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

Piper Sandler raised the firm’s price target on Amgen (AMGN) to $329 from $310 and keeps an Overweight rating on the shares. The firm notes the ...

THOUSAND OAKS, Calif., Feb. 7, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 35 th Annual Oppenheimer Healthcare Life Sciences Conference at 11:20 a.m. ET on Wednesday, Feb. 12, 2025.

In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other stocks that Jim Cramer discusses that are leading the Dow higher in 2025. On Thursday ...

Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just ...

SEC Filings provided by EDGAR Online, Inc.

After hours: 7:56:38 pm GMT-5 ...